All In Biotech

Drug Trial Radar · NCT03347422

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion

Last checked: Nov 20, 2026Latest source record: Dec 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

42

Actual

Start

Mar 17, 2018

Primary completion

Dec 3, 2021

Study completion Dec 3, 2021

Sponsor

Lead sponsor
Bioverativ, a Sanofi companySanofi (SNY)
Sponsor type
Industry
First posted
Nov 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (\>=)1.5 grams per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants with primary cold agglutinin disease (CAD) without a recent history of blood transfusion. The purpose of Part B was to evaluate the long-term safety and tolerability of sutimlimab in participants with primary CAD.

Conditions

  • Cold Agglutinin Disease

Interventions

  • sutimlimab (BIVV009)Drug

    Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)

  • placeboDrug

    Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants With Response to TreatmentTime frame: From Week 5 through Week 26
  2. Part B: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Time frame: Part B, 6.5 g cohort: From first dose (Week 26) up to 149 weeks of treatment + 9 weeks of follow-up (i.e., up to Week 184); Part B, 7.5 g cohort: From first dose (Week 26) up to 137 weeks of treatment + 9 weeks of follow-up (i.e., up to Week 172)

Locations

53 sites in 14 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates PC

    Tucson, Arizona

  • USC/Keck School of Medicine

    Los Angeles, California

  • Georgetown University Medical Center

    Georgetown, District of Columbia

  • Cleveland Clinic Florida

    Weston, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Montefiore Medical Center

    New York, New York

  • New York Medical College at Westchester Medical Center

    Valhalla, New York

  • East Carolina University

    Greenville, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • UW Hospitals and Clinics

    Madison, Wisconsin

  • USC Health Clinics

    Buderim, Queensland, Australia

  • Ballarat Oncology & Haematology

    Ballarat, Victoria, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Perth Blood Institute

    West Perth, Western Australia, Australia

  • Medical University of Vienna

    Vienna, Austria

  • ZNA Stuivenberg

    Antwerp, Belgium

  • University Hospitals Leuven

    Leuven, Belgium

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • McGill University Health Center

    Montreal, Quebec, Canada

  • CHU d'Angers

    Angers, France

  • Hôpital de Caen

    Caen, France

  • Centre Hospitalier Henri Mondor

    Créteil, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Gemeinschaftspraxis Hämatologie-Onkologie

    Dresden, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Univ Ulm, Inst Klin. Transfusions. Immungen

    Ulm, Germany

  • Hadassah Medical Center

    Jerusalem, Israel

  • Laniado Hospital

    Netanya, Israel

  • A. O. Spedali Civili di Brescia

    Brescia, Italy

  • Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • U.O.C. Ematologia- Policlinico "A. Gemelli"

    Rome, Italy

  • U.O.C. Ematologia Ospedale San Bortolo

    Vicenza, Italy

  • Aichi Medical University Hospital

    Nagakute, Japan

  • Japanese Red Cross Society Himeji Hospital

    Himeji, Hyōgo, Japan

  • Ishikawa Prefectural Central Hospital

    Kanazawa, Ishikawa-ken, Japan

  • Tokai University Hospital

    Isehara, Kanagawa, Japan

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.